Human monoclonal antibodies targeting rabies glycoprotein have been proposed as a potential alternative to rabies immunoglobulin to neutralise rabies virus at the wound site until sufficient virus ...

Neutralising monoclonal antibodies (NAbs) are being developed for future respiratory virus threats, notably highly pathogenic ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Researchers from the Broad Institute and Mass General Brigham found that low-oxygen environments can protect neurons and ...

On Bone & Joint Day 2025, experts share advice on prevention, early care, and mobility solutions to keep you active and ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

This study offers useful findings demonstrating the cartilage-protective effects of osteoactivin in inflammatory experimental models. The study provides compelling evidence that osteoactivin may serve ...

US AI-focused start-up Formation Bio and IMIDomics, a precision medicine company focused on immune-mediated inflammatory ...

Wouldn’t it be great if, instead of getting a fake tooth implanted, you could grow a new one? Japanese scientists are working ...

Formation Bio Inc. has licensed worldwide rights to Imidomics Inc.’s potentially first-in-class anti-CD226 monoclonal ...

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in ...

Investing.com -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) stock surged 32.9% premarket following the publication of a peer-reviewed article validating the disease-modifying potential of its ...